Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 13, 2026, 8:23 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 313–336 of 2,347 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: COVID-19 SARS-CoV-2 Infection Clear all
Completed No phase listed Observational

Cognitive Assessment in COVID-19 Positive Patients Using the DANA App

NCT05143333
View directory record Official record
Conditions
COVID-19
Interventions
DANA app
Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 65 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 11, 2022 · Synced Oct 13, 2026, 8:23 PM EDT
Terminated Phase 2 Interventional Results available

Open Label Extension of Efgartigimod in Adults With Post-COVID-19 POTS

NCT05918978
View directory record Official record
Conditions
Post-COVID Postural Orthostatic Tachycardia Syndrome Postural Orthostatic Tachycardia Syndrome
Interventions
Efgartigimod
Drug
Lead sponsor
argenx
Industry
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
9
States / cities
La Jolla, California • Palo Alto, California • Glenview, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2025 · Synced Oct 13, 2026, 8:23 PM EDT
Terminated Phase 3 Interventional Results available

Double-blind, Randomized, Placebo-controlled Study Evaluating Efficacy and Safety of IgPro20 in Post-COVID-19 POTS

NCT06524739
View directory record Official record
Conditions
Post-COVID Postural Orthostatic Tachycardia Syndrome
Interventions
IgPro20, Placebo
Biological
Lead sponsor
CSL Behring
Industry
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
34
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 29 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 13, 2026, 8:23 PM EDT
Completed Not applicable Interventional

Evaluating a Comprehensive Multimodal Outpatient Rehabilitation Program for PASC Program to Improve Functioning of Persons Suffering From Post-COVID-19 Syndrome: A Randomized Controlled Trial

NCT06156202
View directory record Official record
Conditions
Post-Acute COVID-19, Post-Acute COVID-19 Syndrome, Post-Acute COVID-19 Infection, Long COVID, Long Covid19, Dyspnea, Orthostasis, Cognitive Impairment
Interventions
Comprehensive Rehabilitation, Augmented Usual Care
Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
Not listed
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 20, 2026 · Synced Oct 13, 2026, 8:23 PM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

PATCH 2&3:Prevention & Treatment of COVID-19 (Severe Acute Respiratory Syndrome Coronavirus 2) With Hydroxychloroquine

NCT04353037
View directory record Official record
Conditions
Coronavirus, Corona Virus Infection
Interventions
Group 1 HCQ, Group 2 Placebo
Drug
Lead sponsor
UnitedHealth Group
Industry
Eligibility
18 Years to 75 Years
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 19, 2021 · Synced Oct 13, 2026, 8:23 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety and Acceptability of Q GRFT Nasal Spray for COVID-19 Prophylaxis

NCT05180500
View directory record Official record
Conditions
COVID-19, Pharmacokinetics, Safety
Interventions
Q-Griffithsin, Placebo
Drug
Lead sponsor
Sharon Hillier
Other
Eligibility
18 Years to 55 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 23, 2024 · Synced Oct 13, 2026, 8:23 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

WEAICOR: Wearables to Investigate the Long Term Cardiovascular and Behavioral Impacts of COVID-19

NCT04605965
View directory record Official record
Conditions
Covid19, Cardiovascular Complication, Behavioral Changes
Interventions
Not listed
Lead sponsor
Tulane University
Other
Eligibility
18 Years to 120 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2025
U.S. locations
2
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Mar 5, 2026 · Synced Oct 13, 2026, 8:23 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Trusted Messengers: Intervention to Promote COVID-19 Vaccination

NCT04981392
View directory record Official record
Conditions
Covid19, Vaccination
Interventions
Primary care text message outreach to unvaccinated patients and resources to support PCPs
Behavioral
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
18 Years and older
Enrollment
21,844 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 26, 2024 · Synced Oct 13, 2026, 8:23 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Simultaneous mRNA COVID-19 and IIV Vaccination in Pregnancy Study

NCT06503900
View directory record Official record
Conditions
Birth Outcomes, Safety, Adverse Event Following Immunization
Interventions
mRNA COVID-19 vaccine, IIV4 (quadrivalent inactivated influenza vaccine)
Biological
Lead sponsor
Duke University
Other
Eligibility
18 Years and older · Female only
Enrollment
98 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
6
States / cities
Atlanta, Georgia • Boston, Massachusetts • Durham, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 13, 2026, 8:23 PM EDT
Not listed No phase listed Observational

Cardiovascular Manifestations of COVID-19

NCT04335630
View directory record Official record
Conditions
Cardiovascular Diseases, COVID
Interventions
Electrocardiogram, telemetry, echocardiogram, laboratory values
Diagnostic Test
Lead sponsor
Memorial Hermann Health System
Other
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 7, 2020 · Synced Oct 13, 2026, 8:23 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Obesity, Insulin Resistance, and PASC: Persistent SARS-CoV-2

NCT05833217
View directory record Official record
Conditions
Long COVID, Insulin Resistance, Insulin Sensitivity
Interventions
Adipose Tissue Biopsy, Steady State Plasma Glucose (SSPG) Test
Procedure · Diagnostic Test
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 80 Years
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
2
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Dec 4, 2024 · Synced Oct 13, 2026, 8:23 PM EDT
Terminated Phase 2 Interventional Results available

Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19

NCT04358068
View directory record Official record
Conditions
COVID-19, SARS-CoV 2
Interventions
Hydroxychloroquine (HCQ), Azithromycin (Azithro), Placebo for Hydroxychloroquine, Placebo for Azithromycin
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
11
States / cities
Birmingham, Alabama • San Diego, California • Torrance, California + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 16, 2021 · Synced Oct 13, 2026, 8:23 PM EDT
Completed Not applicable Interventional

Text4Vax: Text Message Reminders for Pediatric COVID-19 and Influenza Vaccines 2024-25 Season

NCT06603090
View directory record Official record
Conditions
Influenza, COVID-19, Vaccination Hesitancy
Interventions
Text message influenza vaccine reminders, Text message COVID-19 vaccine reminders, Text message influenza and COVID-19 vaccine reminders
Behavioral
Lead sponsor
Columbia University
Other
Eligibility
6 Months to 17 Years
Enrollment
66,147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
4
States / cities
Itasca, Illinois • New York, New York • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 11, 2025 · Synced Oct 13, 2026, 8:23 PM EDT
Completed No phase listed Observational

eVusheld Assessment reaL wORld Effectiveness in DoD Health System

NCT05569408
View directory record Official record
Conditions
COVID-19; SARS-CoV-2; 2019 Novel Coronavirus Disease
Interventions
EVUSHELD
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
12 Years and older
Enrollment
4,724 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 13, 2026, 8:23 PM EDT
Recruiting Phase 3 Interventional

A Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely Immunocompromised

NCT07013474
View directory record Official record
Conditions
COVID-19 Infection
Interventions
ibuzatrelvir, remdesivir, placebo for ibuzatrelvir, placebo for remdesivir
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
69
States / cities
Canoga Park, California • Granada Hills, California • La Jolla, California + 25 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 13, 2026, 8:23 PM EDT
Not listed Phase 1 Interventional

Safety, Tolerability and Pharmacokinetics of Inhaled Nanoparticle Formulation of Remdesivir (GS-5734) and NA-831

NCT04480333
View directory record Official record
Conditions
Covid19, Corona Virus Infection, Severe Acute Respiratory Syndrome, Severe Acute Respiratory Infection, Severe Acute Respiratory Syndrome (SARS) Pneumonia, Severe Acute Respiratory Syndrome of Upper Respiratory Tract, Neurodegeneration, Neuroinflammatory Response
Interventions
Drug: NA-831 - 0.10 mg/kg, Placebo- 0.10 mg/kg, Drug: NA-831 - 0.20 mg/kg, Placebo- 0.20 mg/kg, Drug: GS-5734 - 1.00 mg/kg, Placebo- 1.00 mg/kg, Drug: GS-5734 - 2.00 mg/kg, Placebo- 2.00 mg/kg, Drugs: NA-831 (0.10 mg/kg) plus GS-5734 (1.00 mg/kg), Placebo 0.10 mg + 1.00 mg/kg, Drugs: NA-831 (0.20 mg/kg) plus GS-5734 (2.00 mg/kg), Placebo 0.20 mg + 2.00 mg/kg
Drug · Combination Product
Lead sponsor
Biomed Industries, Inc.
Industry
Eligibility
21 Years to 50 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Sunnyvale, California
Source: ClinicalTrials.gov public record
Updated Jul 21, 2020 · Synced Oct 13, 2026, 8:23 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

The COVID-19 and Healthcare Workers: An Active Intervention

NCT04497415
View directory record Official record
Conditions
Brief Video-based Intervention, Non Intervention Control
Interventions
Video-Based intervention
Other
Lead sponsor
Research Foundation for Mental Hygiene, Inc.
Other
Eligibility
18 Years to 80 Years
Enrollment
350 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 14, 2022 · Synced Oct 13, 2026, 8:23 PM EDT
Completed Phase 1 Interventional

Cyclosporine in Patients With Moderate COVID-19

NCT04412785
View directory record Official record
Conditions
COVID-19
Interventions
Cyclosporine
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 11, 2022 · Synced Oct 13, 2026, 8:23 PM EDT
Completed Not applicable Interventional

Clinical Evaluation of the Panbio™ COVID-19/Flu A&B Panel

NCT06127108
View directory record Official record
Conditions
COVID-19, Influenza A, Influenza B
Interventions
Panbio™
Diagnostic Test
Lead sponsor
Abbott Rapid Dx
Industry
Eligibility
2 Years and older
Enrollment
447 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Vienna, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 25, 2024 · Synced Oct 13, 2026, 8:23 PM EDT
Completed Phase 2 Interventional Results available

A Study to Assess the Efficacy and Safety of Gimsilumab in Subjects With Lung Injury or Acute Respiratory Distress Syndrome Secondary to COVID-19 (BREATHE)

NCT04351243
View directory record Official record
Conditions
COVID-19
Interventions
Gimsilumab, Placebo
Drug
Lead sponsor
Kinevant Sciences GmbH
Industry
Eligibility
18 Years and older
Enrollment
227 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
33
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 21 more
Source: ClinicalTrials.gov public record
Updated Dec 14, 2021 · Synced Oct 13, 2026, 8:23 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Impact of Reactogenicity of the 2024-2025 COVID-19 Vaccines on Health Care Workers and First Responders in the United States

NCT06633835
View directory record Official record
Conditions
COVID-19, Vaccine-Preventable Diseases, SARS CoV 2 Infection
Interventions
protein subunit: Novavax COVID-19 vaccine, Pfizer mRNA COVID-19 vaccine
Biological
Lead sponsor
Novavax
Industry
Eligibility
18 Years and older
Enrollment
660 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Oct 13, 2026, 8:23 PM EDT
Completed No phase listed Observational

Prognostic Value of Point of Care Cardiac and Lung Ultrasound in COVID-19

NCT04379544
View directory record Official record
Conditions
Coronavirus, Respiratory Failure
Interventions
Observation only
Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 100 Years
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 21, 2023 · Synced Oct 13, 2026, 8:23 PM EDT
Completed Phase 2 Interventional

LEAP-CT for Treatment of COVID-19 Patients (Master Protocol)

NCT05077332
View directory record Official record
Conditions
2019 Novel Coronavirus Disease, 2019 Novel Coronavirus Infection, 2019-nCoV Disease, 2019-nCoV Infection, COVID-19 Pandemic, COVID-19 Virus Disease, COVID-19 Virus Infection, Covid19, Coronavirus Disease 2019, SARS-CoV-2 Infection, SARS-CoV-2 Acute Respiratory Disease, COVID-19
Interventions
Famotidine, Celecoxib, Placebo
Drug · Other
Lead sponsor
Leidos Life Sciences
Industry
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Dec 16, 2025 · Synced Oct 13, 2026, 8:23 PM EDT
Completed No phase listed Observational

COVID-19 Antibody Levels After Vaccines

NCT04944134
View directory record Official record
Conditions
Vaccine Preventable Disease
Interventions
COVID-19 Vaccination
Biological
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
71 participants
Timeline
2021 – 2022
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 1, 2022 · Synced Oct 13, 2026, 8:23 PM EDT